vTv Therapeutics (VTVT) AI Stock Analysis

• Market Cap: $150.44M
• Dividend Yield: N/A
• Average Volume (3M): 5.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: -98.30%
• EPS Growth: 26.62%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.58
• Shares Outstanding: 3,938,018
• 10 Day Avg. Volume: 5,801
• 30 Day Avg. Volume: 5,072
• PEG Ratio: 0.00
• Price to Book (P/B): 5.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.34
• Enterprise Value/Market Cap: 0.04
• Enterprise Value/Revenue: -220.32
• Enterprise Value/Gross Profit: -440.64
• Enterprise Value/Ebitda: -0.16
• 1Y Price Target: $53.33
• Price Target Upside: 48.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -3.98
• Revenue Forecast (FY): $4.00M

• Rating: 48 Neutral
• Price Target: $38.00 ▲(5.56% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is primarily held down by weak financial performance (no consistent revenue, sizable losses, and sustained cash burn). Technicals are modestly supportive with the stock above major moving averages, but momentum is not strong. Valuation is constrained by loss-making results and no dividend, while recent corporate events provide a meaningful positive offset through cash runway visibility and partnership-driven funding potential.

Positive Factors

Cash runway and recent $20M receipt

A large cash balance plus a February 2026 $20M inflow materially extends runway beyond the anticipated CATT1 topline readout. This reduces near-term dilution pressure, allows continued Phase 3 execution and business development, and gives management time to pursue non-dilutive deals or commercial planning.

Low leverage and improved equity position

Near-zero debt lowers solvency risk and fixed financial obligations, while a materially improved equity base strengthens the balance sheet. This structural improvement enhances the company's ability to fund development, negotiate partnerships, and withstand R&D volatility without immediate bankruptcy risk.

Cadisegliatin in Phase 3 with FDA Breakthrough

A late-stage program with Breakthrough designation targets a large unmet type 1 diabetes market and represents a potential first-in-class oral adjunctive therapy. Successful Phase 3 execution would structurally transform the company from research-stage to commercial/partnering opportunities, altering long-term revenue prospects.

Negative Factors

No recurring product revenue

The absence of product revenue means vTv lacks operating cash inflows and is highly dependent on financing, milestones or partnerships. That structural dependence increases funding risk: until a product is commercialized or licensed, sustainable self-funding is unlikely and dilution risk persists.

Consistent operating cash burn

Sustained negative operating cash flow shows R&D and operating costs translate into real cash outflows. Persistent burn at this magnitude will necessitate further capital or non-dilutive deals if development timelines slip, creating structural financing pressure over the medium term.

Persistent net losses and negative margins

Large, recurring net losses and deeply negative margins indicate core operations are not profitable and R&D spending outpaces any revenue. Even with improved equity, continued losses suppress returns and mean the company remains dependent on external funding or successful asset monetization to achieve sustainable finances.

vTv Therapeutics Business Overview & Revenue Model

Company Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

How the Company Makes Money

As a clinical-stage biopharmaceutical company, vTv Therapeutics does not typically generate recurring product revenue because its drug candidates are not broadly commercialized. The company’s funding and revenue model is generally driven by (1) research and development financing (primarily through equity offerings and other capital-raising activities) and (2) collaboration or licensing arrangements where it may receive upfront payments, milestone payments, and/or reimbursement for certain development costs, and potentially royalties if a partnered product reaches the market. Specific, current details on material partnerships, milestone structures, royalty rates, or the magnitude and timing of such payments are not available here (null). If the company has any minor revenue from grants or other sources, those details are also not available here (null).

vTv Therapeutics Financial Statement Overview

Summary

Financials reflect an early-stage biotech risk profile: revenue is minimal/volatile (down to $0 in 2025) with large, persistent net losses and ongoing cash burn (operating cash flow about -$25M in both 2024 and 2025). The key offset is low leverage (near-zero debt) and a materially improved equity position in 2024–2025, which reduces near-term solvency risk but does not resolve the funding needs implied by negative free cash flow.

Income Statement

The company has not established a stable revenue base (revenue fell to $0 in 2025 vs. $1.0M in 2024, after $0 in 2023), and profitability remains weak with persistent net losses (net income was -$27.0M in 2025 vs. -$18.5M in 2024). Margins are heavily negative in years with revenue (e.g., 2024 net margin ~-18x revenue), reflecting a cost structure that is not supported by current sales levels. A modest positive is that gross profit is strong when revenue exists (100% gross margin in 2024/2022/2021), but the operating loss profile dominates the overall earnings quality.

Balance Sheet

Leverage is low (total debt is $0 in 2025 and only $0.17M in 2024), which reduces financial risk. Equity has improved materially, moving from negative in 2020–2023 to positive in 2024 ($12.2M) and 2025 ($64.4M), supporting a stronger capital base. However, returns remain poor given continued losses (return on equity is negative in 2024 and 2025), and the balance sheet’s strength ultimately depends on ongoing funding until profitability improves.

Cash Flow

Cash generation is a key weakness: operating cash flow and free cash flow are consistently negative (2025 operating cash flow -$25.3M; 2024 -$25.3M; 2023 -$19.1M). Free cash flow deterioration has not been arrested, and while 2025 shows positive free cash flow growth (+21.2%), this is off a deeply negative base and still implies a significant cash burn. Free cash flow roughly matches net losses (free cash flow to net income ~1.0 in most years), indicating losses are translating into real cash outflows rather than being primarily non-cash.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	1.02M	0.00	2.02M	4.00M
Gross Profit	-16.00K	1.02M	0.00	2.02M	4.00M
EBITDA	-32.79M	-22.52M	-25.86M	-24.77M	-17.52M
Net Income	-26.97M	-18.46M	-20.25M	-19.16M	-12.99M
Balance Sheet
Total Assets	89.90M	38.27M	11.02M	33.24M	25.47M
Cash, Cash Equivalents and Short-Term Investments	88.93M	36.75M	9.45M	12.13M	13.41M
Total Debt	0.00	169.00K	529.00K	716.00K	932.00K
Total Liabilities	25.46M	23.96M	29.57M	27.40M	10.25M
Stockholders Equity	64.44M	12.20M	-24.68M	-10.74M	-9.74M
Cash Flow
Free Cash Flow	-25.25M	-25.31M	-19.08M	-15.27M	-19.31M
Operating Cash Flow	-25.25M	-25.31M	-19.08M	-15.25M	-19.31M
Investing Cash Flow	0.00	0.00	4.40M	-21.00K	0.00
Financing Cash Flow	77.44M	52.61M	12.00M	13.98M	26.98M

vTv Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 36.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Positive. The current price of 36 is below the 20-day moving average (MA) of 36.33, above the 50-day MA of 35.66, and above the 200-day MA of 25.57, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 59.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTVT.

vTv Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADAG	53 Neutral	$171.09M	-1.36	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLNN	50 Neutral	$62.72M	―	240.83%	―	-49.17%	23.37%
PLRX	49 Neutral	$79.87M	-0.79	-69.56%	―	―	14.19%
VTVT	48 Neutral	$150.44M	-12.49	-100.49%	―	-98.30%	26.62%
ATHE	46 Neutral	$53.53M	-2.07	-30.19%	―	―	63.85%
IFRX	46 Neutral	$63.11M	-1.58	-68.47%	―	―	―

vTv Therapeutics Corporate Events

vTv Therapeutics Highlights Cadisegliatin Phase 3 and Cash Runway

On March 10, 2026, vTv Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on diabetes and other metabolic and immune-related diseases, posted an updated corporate slide presentation highlighting its late-stage pipeline and financial position. The presentation underscores cadisegliatin, a hepatoselective glucokinase activator with FDA Breakthrough designation, as a potential first oral adjunctive therapy for type 1 diabetes in the U.S., targeting a market where roughly 1.5 million patients currently lack such options and about 75% fail to reach American Diabetes Association glycemic targets.

The update details that cadisegliatin has been dosed in more than 500 subjects, has shown positive effects on hypoglycemia and HbA1c in earlier studies, and is now in Phase 3 with completion of CATT1 trial enrollment expected in the third quarter of 2026, signaling a critical upcoming catalyst for the company. vTv also highlights an $88.9 million year-end 2025 cash balance plus an additional $20 million received in February 2026, providing funding runway beyond the anticipated CATT1 topline readout, which, combined with a broader pipeline in immunology, metabolism and oncology, positions the company to pursue both commercial and partnership opportunities in an underserved and growing global type 1 diabetes market.

The materials emphasize the significant unmet need and safety challenges in type 1 diabetes management, particularly the burden of hypoglycemia and the lack of FDA-approved oral adjunctive therapies since the introduction of insulin, framing cadisegliatin’s mechanism as a liver-targeted approach to improving glucose homeostasis. For investors and other stakeholders, the March 2026 presentation serves as both a scientific and strategic update, reinforcing vTv’s focus on late-stage execution in type 1 diabetes while flagging the potential for non-dilutive funding from its other differentiated clinical assets.

The most recent analyst rating on (VTVT) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.

vTv Therapeutics Highlights Cadisegliatin Progress and Financial Strength

On February 26, 2026, vTv Therapeutics posted an updated corporate slide presentation outlining the progress of cadisegliatin, its late-stage oral adjunctive therapy candidate for type 1 diabetes, and its broader pipeline. The company highlighted the unmet need in type 1 diabetes, where about 75% of U.S. patients fail to reach recommended HbA1c targets and no oral adjunctive therapies are approved, positioning cadisegliatin—now in Phase 3 with topline CATT1 data expected in the second half of 2026, and backed by prior Phase 1 and Phase 2 data and FDA Breakthrough designation—as a potential first-in-class solution.

The presentation also emphasized vTv’s financial strength, citing $98.5 million in cash as of September 30, 2025, plus $20 million received on February 2, 2026, supporting operations well past the anticipated Phase 3 readout. With a seasoned leadership team and a pipeline of differentiated assets in multiple therapeutic areas, the update signals that vTv is positioning itself to capitalize on a large, long-underserved market in type 1 diabetes while pursuing additional partnering and funding opportunities across its portfolio.

The most recent analyst rating on (VTVT) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.

vTv Therapeutics Expands Global HPP737 Rights with Newsoara

On January 30, 2026, vTv Therapeutics LLC amended its 2018 license agreement with Newsoara Biopharma, restoring and significantly expanding Newsoara’s rights to develop and commercialize the PDE4 inhibitor HPP737 on a worldwide basis, contingent on a $20 million upfront payment. Under the revised terms, vTv stands to receive up to $50 million in development milestone payments, $65 million in sales-related milestones, and mid-single-digit royalties on sales, positioning the company to secure substantial non-dilutive funding and broader global exposure for HPP737, with potential upside for both its revenue profile and partnership-driven growth strategy.

The most recent analyst rating on (VTVT) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.